ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,142.00
-0.13%
S&P ASX All Technology
3,417.00
0.40%
Brent Oil
74.605
1.18%
US Dollar vs AUD
1.45262
-0.73%
Bitcoin
63,719.97
0.62%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateTimeSourceHeadlineSymbolCompany
23/09/202421:00Business WireDatopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trialNASDAQ:AZNAstraZeneca PLC
23/09/202420:44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
23/09/202420:32IH Market NewsApollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and MoreNASDAQ:AZNAstraZeneca PLC
23/09/202420:27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
21/09/202406:34Business WireFLUMIST approved for self-administration in the USNASDAQ:AZNAstraZeneca PLC
18/09/202421:00Business WireFASENRA approved in the US for eosinophilic granulomatosis with polyangiitisNASDAQ:AZNAstraZeneca PLC
18/09/202401:22GlobeNewswire Inc.International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024NASDAQ:AZNAstraZeneca PLC
16/09/202421:00Business WireIMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trialNASDAQ:AZNAstraZeneca PLC
16/09/202400:30Business WireIMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trialNASDAQ:AZNAstraZeneca PLC
14/09/202400:00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastasesNASDAQ:AZNAstraZeneca PLC
11/09/202400:28PR Newswire (US)SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy TestingNASDAQ:AZNAstraZeneca PLC
11/09/202400:16PR Newswire (US)SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy TestingNASDAQ:AZNAstraZeneca PLC
10/09/202420:02IH Market NewsApple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9%NASDAQ:AZNAstraZeneca PLC
10/09/202403:50Business WireDatopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trialNASDAQ:AZNAstraZeneca PLC
09/09/202402:25Business WireNovel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trialNASDAQ:AZNAstraZeneca PLC
05/09/202420:11IH Market NewsQualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual ListingNASDAQ:AZNAstraZeneca PLC
03/09/202421:00Business WireAstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024NASDAQ:AZNAstraZeneca PLC
23/08/202422:20IH Market NewsCruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1%NASDAQ:AZNAstraZeneca PLC
16/08/202421:00Business WireIMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgeryNASDAQ:AZNAstraZeneca PLC
16/08/202420:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
15/08/202421:00Business WireIMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the USNASDAQ:AZNAstraZeneca PLC
30/07/202420:26Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
30/07/202420:00IH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNASDAQ:AZNAstraZeneca PLC
29/07/202421:00Business WireFixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trialNASDAQ:AZNAstraZeneca PLC
29/07/202420:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
25/07/202421:00Business WireAstraZeneca’s H1 and Q2 2024 Financial ResultsNASDAQ:AZNAstraZeneca PLC
25/07/202420:21IH Market NewsU.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire ExpectationsNASDAQ:AZNAstraZeneca PLC
25/07/202420:19IH Market NewsEarnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5%NASDAQ:AZNAstraZeneca PLC
23/07/202421:00PR Newswire (Canada)Voydeya est approuvé au Canada à titre de traitement d'appoint au ravulizumab ou à l'éculizumab chez les adultes atteints d'une maladie rare, appelée HPN, qui présentent une anémie hémolytique résiduelle attribuable à une hémolyse extravasculairNASDAQ:AZNAstraZeneca PLC
23/07/202421:00PR Newswire (Canada)Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysisNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Your Recent History

ASX
BHP
BHP
ASX
TLS
Telstra
ASX
XMM
S&P ASX 300 Metals and M...
NYSE
XOM
Exxon Mobil
ASX
MQG
Macquarie
NASDAQ
AMZN
Amazon.com
PM
XAUUSD
Gold vs US Dollar
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
VZ
Verizon Communications
CCOM
SILVER
SILVER
COIN
AVAXUSD
Avalanche
ASX
XFL
S&P ASX 50
ASX
NCM
Newcrest Mining
NYSE
MRK
Merck
ASX
WOW
Woolworths
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved